The European Journal of Health Economics

, Volume 13, Issue 4, pp 375–378 | Cite as

Coping with uncertainty on health decisions: assessing new solutions

  • Fernando AntoñanzasEmail author
  • Roberto Rodríguez-Ibeas
  • Carmelo A. Juárez-Castelló


Uncertainty is present in most human decisions. The introduction of health technologies in publicly funded systems is no exception. Sources of uncertainty in this domain come from different grounds, and a variety of means and tools have been developed to cope with unknown parameters and uncertain variables.

Clinical trials were established more formally back in the 1950s and 1960s of the last century in most developed countries as a requirement to reduce uncertainties in general and primarily to guarantee safety and, later, efficacy. The outcomes of such clinical trials allowed us to understand the features of a given agent under certain controlled specific conditions, usually by comparing its medical performance versus a placebo. They have provided basic knowledge for registration, and to fix the price and reimbursement conditions for the majority of new drugs for several decades. However, in order to use this information on drugs, health authorities and physicians had to...


  1. 1.
    Antoñanzas, F., Juárez, C., Rodríguez, R., Lorente, M.R., Hutter, M.F., Pinillos, M.: Transferability of results of the economic evaluation of health technologies. Health Econ. 18, 629–643 (2009)CrossRefPubMedGoogle Scholar
  2. 2.
    Boulenger, S., Nixon, J., Drummond, M., Ullman, P., Rice, S., De Pouvourville, G.: Can economic evaluations be more transferable? Eur. J. Health Econ. 6(4), 334–346 (2005)CrossRefPubMedGoogle Scholar
  3. 3.
    Briggs, A., Ritchie, K., Fenwick, E., et al.: Access with evidence development in the UK. Pharmacoeconomics 28(2), 163–170 (2010)CrossRefPubMedGoogle Scholar
  4. 4.
    Claxton, K., Sculpheer, M.: Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 24(11), 1055–1068 (2006)CrossRefPubMedGoogle Scholar
  5. 5.
    Coyle, D., Oakley, J.: Estimating the perfect value of partial perfect information: a review of methods. Eur. J. Health Econ. 9(3), 251–259 (2008)CrossRefPubMedGoogle Scholar
  6. 6.
    Drummond, M., Mason, A., Towse, A.: The desirability and feasibility of economic studies of drugs post-launch. Eur. J. Health Econ. 7(1), 5–6 (2006)CrossRefPubMedGoogle Scholar
  7. 7.
    Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ullman, P., De Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10(2), 157–165 (2009)CrossRefPubMedGoogle Scholar
  8. 8.
    Stafinski, T., McCabe, C.J., Menon, D.: Funding unfundable. Pharmacoeconomics 28(2), 113–142 (2010)CrossRefPubMedGoogle Scholar
  9. 9.
    Towse, A., Garrison, L.P.: Can′t get no satisfaction? Will pay for performance help? Pharmacoeconomics 28(2), 93–102 (2010)CrossRefPubMedGoogle Scholar
  10. 10.
    Trueman, P., Drummond, M., Hutton, J.: Developing guidance for budget impact analysis. Pharmacoeconomics 19(6), 609–621 (2001)CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Fernando Antoñanzas
    • 1
    Email author
  • Roberto Rodríguez-Ibeas
    • 1
  • Carmelo A. Juárez-Castelló
    • 1
  1. 1.Department of EconomicsUniversity of La RiojaLogroñoSpain

Personalised recommendations